Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 119 clinical trials
None
Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr

Non Small Cell lung cancer (NSCLC) remains the first cause of death by cancer in the World. For the patients presenting a NSCLC stage IV, the median of survival is about 15 months today. The chemotherapy with platinum is the standard treatment for these patients but immunotherapy showed these efficacy …

pd-l1
cancer
ipilimumab
nivolumab
metastasis
  • 22 views
  • 25 Jan, 2021
  • 46 locations
None
SAR408701 Versus Docetaxel in Previously Treated Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients

Primary Objectives: Study is designed with two primary endpoints that will be analyzed on randomized participants at the time of the cutoff date for each given analysis (progression free survival [PFS] and overall survival [OS]). Study success is defined either on PFS or OS The primary objective is to determine …

squamous non-small cell lung cancer
platinum-based chemotherapy
docetaxel
cancer
measurable disease
  • 23 views
  • 22 Oct, 2021
  • 422 locations
None
SAR408701 in Combination With Ramucirumab in Pre-treated Patients With Non Squamous Non-small Cell Lung Cancer (NSQ NSCLC)

Primary Objectives: Part 1 (safety run-in): To assess the tolerability and to confirm the recommended dose of SAR408701 in combination with ramucirumab in the NSQ NSCLC population. Part 2: To assess the antitumor activity of SAR408701 in combination with ramucirumab in the NSQ NSCLC population. Secondary Objectives: To assess the …

squamous non-small cell lung cancer
measurable disease
platinum-based chemotherapy
cancer
  • 0 views
  • 07 Oct, 2021
  • 18 locations
None
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

This study will compare the effectiveness of osimertinib alone with the combination of osimertinib and chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a

pemetrexed
cancer
EGFR
metastasis
gilbert's syndrome
  • 0 views
  • 31 Aug, 2021
  • 11 locations
None
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

called MET, within a specific part of the gene called exon 14. Approximately 90 people with advanced or metastatic lung cancer, with these specific mutations in the MET gene but without changes in

cancer chemotherapy
docetaxel
systemic therapy
measurable disease
EGFR
  • 0 views
  • 18 Jul, 2021
  • 44 locations
None
Feasibility of an Acute Physical Exercise Before Treatment Infusion for Metastatic Lung Cancer Patients

Because of metastatic Non-Small Cell Lung Cancer (mNSCLC) and its treatments, patients suffer from numerous symptoms such as dyspnea, muscle atrophy, pain, fatigue, loss of appetite, altered physical condition and lung function, which may further impair the patient's overall condition. Nevertheless, it has been suggested that physical exercise could improve …

  • 0 views
  • 24 Feb, 2021
  • 1 location
None
Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer

Trial Design Patients with stage IV non-small cell lung cancer are randomized to nivolumab/ipilimumab plus either sequential or concurrent stereotactic body radiotherapy (SBRT). The primary endpoint is the phase I safety endpoint of SBRT dose for each body site. The same starting SBRT dose levels are used in each arm. …

  • 11 views
  • 27 Jan, 2021
  • 1 location
None
Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)

ROS1 rearrangements are present in 1-2% of NSCLC cases and define a distinct molecular subgroup. Like ALK (anaplastic lymphoma kinase) rearrangements in NSCLC, ROS1 fusions confer sensitivity to the inhibitor crizotinib. Crizotinib, which is a tyrosine kinase inhibitor (TKI), has been shown to be effective in tumors in several retrospective …

  • 0 views
  • 07 Jun, 2021
  • 39 locations
None
Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients

Treating Non-small Cell Lung Cancer (NSCLC) Patients with MET exon 14mutations with Savolitinib

  • 0 views
  • 09 Sep, 2021
  • 1 location
None
Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)

The purpose of the study is to determine whether plinabulin (also known as BPI-2358) has an effect on cancer and body in combination with nivolumab, a standard treatment for metastatic squamous non-small cell lung cancer with progression on or after platinum-based chemotherapy. Plinabulin inhibits tumor growth by targeting both new …

squamous non-small cell lung cancer
systemic therapy
cancer
brain metastases
measurable disease
  • 0 views
  • 01 Mar, 2021
  • 1 location